A significant development has emerged in the rapidly expanding litigation surrounding GLP-1 receptor agonist drugs such as Ozempic. The U.S. Judicial Panel on Multidistrict Litigation (JPML) has officially created a new federal multidistrict litigation (MDL) focused specifically on claims that these medications caused non-arteritic anterior ischemic optic neuropathy (NAION) — a serious and often permanent […]
View PostWe work on a contingency basis, which means there are no upfront costs and we don’t get paid any attorney fees unless we win your case and you receive compensation.













